Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.7K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.7K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Hormones of the Pituitary Gland01:27

Hormones of the Pituitary Gland

15.1K
The small, pea-sized pituitary gland is located at the base of the brain. It is crucial in regulating various bodily functions, from growth to reproduction. The gland is divided into the anterior lobe and the posterior lobe. The secretory cell clusters in the pars distalis of the anterior pituitary lobe are controlled by hypothalamic regulators and synthesize six primary hormones.
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
15.1K
Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes - 2026 Update" [Endocrine Practice. 2026;32(4):473-518].

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same author

A potential Adjunctive Role of 7T MRI and Amino-Acid PET in Localizing MRI-Occult Functional Pituitary Microadenomas: A Scoping Review.

AJNR. American journal of neuroradiology·2026
Same author

Consensus on acromegaly complications: an update.

Pituitary·2026
Same author

American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes - 2026 Update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same author

Consensus on acromegaly therapeutic outcomes: an update.

Nature reviews. Endocrinology·2025
Same author

Management of Osilodrostat Therapy in Patients With Cushing's Syndrome: A Modified Delphi Consensus Panel.

Journal of the Endocrine Society·2025
Same journal

Control of muscle mass and accretion.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Multiple endocrine neoplasia type 2: From molecular genetics to precision therapy.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Nutritional advice for patients with obesity and prediabetes.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Effects of prolonged physical training on skeletal muscle mass accrual throughout the life span.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Type 2 diabetes and obesity in South Asian patients with polyendocrine metabolic ovarian syndrome: The emerging role of metabolomics.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Stress and the interaction of the hypothalamic-pituitary-adrenal axis with other pituitary axes and its consequences on muscle mass.

Best practice & research. Clinical endocrinology & metabolism·2026
See all related articles

Related Experiment Video

Updated: Mar 30, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

20.1K

Resistant prolactinomas.

Susan L Samson1

  • 1Departments of Medicine and Neurologic Surgery, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.

Best Practice & Research. Clinical Endocrinology & Metabolism
|March 28, 2026
PubMed
Summary
This summary is machine-generated.

Most prolactinomas respond to dopamine agonist (DA) therapy. However, a minority are resistant, presenting a clinical challenge requiring multimodal treatment strategies for effective management of these pituitary tumors.

Keywords:
amenorrheadopamine agonistgalactorrheahyperprolactinemiapituitary adenomaprolactinomaresistancetranssphenoidal surgery

More Related Videos

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

2.8K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.8K

Related Experiment Videos

Last Updated: Mar 30, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

20.1K
X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

2.8K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.8K

Area of Science:

  • Endocrinology
  • Oncology
  • Genetics

Background:

  • Prolactinomas are the most common functional pituitary adenomas.
  • Most cases respond well to dopamine agonist (DA) therapy.
  • A subset of prolactinomas exhibit resistance to conventional DA doses, posing clinical challenges.

Purpose of the Study:

  • To summarize the characteristics and management of dopamine agonist-resistant prolactinomas.
  • To highlight factors associated with treatment resistance.
  • To discuss current and potential therapeutic strategies.

Main Methods:

  • Review of clinical characteristics associated with DA resistance.
  • Analysis of radiologic and histopathologic features.
  • Discussion of genetic factors (e.g., MEN1, AIP).
  • Evaluation of treatment modalities including DA titration, surgery, radiotherapy, and adjunct therapies.

Main Results:

  • DA resistance is linked to male sex, larger tumor size, cavernous sinus invasion, and high cell proliferation.
  • Germline variants in genes like MEN1 and AIP are implicated in a small fraction of resistant cases.
  • Multimodal treatment is often necessary, involving escalated DA doses, surgery, or radiotherapy.

Conclusions:

  • Prolactinoma treatment resistance necessitates tailored, often multimodal, therapeutic approaches.
  • Further research is needed for non-approved adjunct therapies, though pasireotide shows promise.
  • Understanding factors contributing to DA resistance is crucial for optimizing patient outcomes.